Fifth Ovarian Cancer Consensus Conference : individualized therapy and patient factors
© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com..
This manuscript reports the consensus statements regarding the design and conduct of clinical trials in patients with newly diagnosed and recurrent epithelial ovarian cancer (EOC), following deliberation at the Fifth Ovarian Cancer Consensus Conference (OCCC), held in Tokyo in November 2015. Three important questions were identified for discussion prior to the meeting and achieved consensus during the meeting: (i) What are the most important factors to be evaluated prior to initial therapy? (ii) What are the most important factors to be evaluated specifically in recurrent disease? (iii) Are there specific considerations for special patient subpopulations? In addition, we report a list of important unmet needs compiled during the consensus process, which is intended to guide future research initiatives.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Annals of oncology : official journal of the European Society for Medical Oncology - 28(2017), 4 vom: 01. Apr., Seite 702-710 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
McGee, J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Consensus Development Conference |
|---|
| Anmerkungen: |
Date Completed 02.05.2017 Date Revised 16.03.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/annonc/mdx010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM268305595 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM268305595 | ||
| 003 | DE-627 | ||
| 005 | 20231224222418.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdx010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0894.xml |
| 035 | |a (DE-627)NLM268305595 | ||
| 035 | |a (NLM)28119296 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a McGee, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fifth Ovarian Cancer Consensus Conference |b individualized therapy and patient factors |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.05.2017 | ||
| 500 | |a Date Revised 16.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a This manuscript reports the consensus statements regarding the design and conduct of clinical trials in patients with newly diagnosed and recurrent epithelial ovarian cancer (EOC), following deliberation at the Fifth Ovarian Cancer Consensus Conference (OCCC), held in Tokyo in November 2015. Three important questions were identified for discussion prior to the meeting and achieved consensus during the meeting: (i) What are the most important factors to be evaluated prior to initial therapy? (ii) What are the most important factors to be evaluated specifically in recurrent disease? (iii) Are there specific considerations for special patient subpopulations? In addition, we report a list of important unmet needs compiled during the consensus process, which is intended to guide future research initiatives | ||
| 650 | 4 | |a Consensus Development Conference | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a GCIG | |
| 650 | 4 | |a consensus conference | |
| 650 | 4 | |a individualized therapy | |
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a recommendations | |
| 700 | 1 | |a Bookman, M |e verfasserin |4 aut | |
| 700 | 1 | |a Harter, P |e verfasserin |4 aut | |
| 700 | 1 | |a Marth, C |e verfasserin |4 aut | |
| 700 | 1 | |a McNeish, I |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, K N |e verfasserin |4 aut | |
| 700 | 1 | |a Poveda, A |e verfasserin |4 aut | |
| 700 | 1 | |a Hilpert, F |e verfasserin |4 aut | |
| 700 | 1 | |a Hasegawa, K |e verfasserin |4 aut | |
| 700 | 1 | |a Bacon, M |e verfasserin |4 aut | |
| 700 | 1 | |a Gatsonis, C |e verfasserin |4 aut | |
| 700 | 1 | |a Brand, A |e verfasserin |4 aut | |
| 700 | 1 | |a Kridelka, F |e verfasserin |4 aut | |
| 700 | 1 | |a Berek, J |e verfasserin |4 aut | |
| 700 | 1 | |a Ottevanger, N |e verfasserin |4 aut | |
| 700 | 1 | |a Levy, T |e verfasserin |4 aut | |
| 700 | 1 | |a Silverberg, S |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, B-G |e verfasserin |4 aut | |
| 700 | 1 | |a Hirte, H |e verfasserin |4 aut | |
| 700 | 1 | |a Okamoto, A |e verfasserin |4 aut | |
| 700 | 1 | |a Stuart, G |e verfasserin |4 aut | |
| 700 | 1 | |a Ochiai, K |e verfasserin |4 aut | |
| 700 | 0 | |a participants of the 5th Ovarian Cancer Consensus Conference |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology : official journal of the European Society for Medical Oncology |d 1990 |g 28(2017), 4 vom: 01. Apr., Seite 702-710 |w (DE-627)NLM012606308 |x 1569-8041 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2017 |g number:4 |g day:01 |g month:04 |g pages:702-710 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/annonc/mdx010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2017 |e 4 |b 01 |c 04 |h 702-710 | ||